PartnerRe Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

PartnerRe Asset Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-518	Closed	-$187K	–	327
2016 Q1	$187K	Hold	518	–	–	0.09%	159
2015 Q4	$281K	Sell	518 -881	-63%	-$477K	0.14%	108
2015 Q3	$651K	Buy	1,399 +37	+3%	+$19.9K	0.11%	132
2015 Q2	$695K	Sell	1,362 -219	-14%	-$107K	0.13%	139
2015 Q1	$714K	Hold	1,581	–	–	0.12%	150
2014 Q4	$649K	Buy	1,581 +231	+17%	+$90.8K	0.11%	164
2014 Q3	$487K	Sell	1,350 -345	-20%	-$116K	0.1%	179
2014 Q2	$479K	Sell	1,695 -208	-11%	-$61.6K	0.08%	206
2014 Q1	$571K	Buy	1,903 +12	+0.6%	+$3.7K	0.1%	197
2013 Q4	$520K	Sell	1,891 -97	-5%	-$27.9K	0.09%	206
2013 Q3	$622K	Sell	1,988 -216	-10%	-$56.8K	0.1%	164
2013 Q2	$496K	Buy	+2,204	New	+$513K	0.08%	218

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

PartnerRe Asset Management's REGN Position: Q2 2016 in Review

PartnerRe Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2016, closing a stake of 518 shares — an estimated $187K sold.

PartnerRe Asset Management first reported a position in REGN in Q2 2013 and held it in 12 quarters. The position peaked at $714K in Q1 2015. 542 funds tracked by Wall St. Rank hold REGN as of Q2 2016.

PartnerRe Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
PartnerRe Asset Management sold 518 Regeneron Pharmaceuticals shares in Q2 2016, an estimated $187K.
PartnerRe Asset Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 12 quarters.
PartnerRe Asset Management's Regeneron Pharmaceuticals position peaked at $714K in Q1 2015.
542 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2016.

Based on PartnerRe Asset Management's 13F filing for Q2 2016, filed 14 Jul 2016.